Psychedelic drug developers rise after Trump signals regulatory support

COMPASS Pathways

20/04/2026 10:16

** Shares of psychedelic drug developers rise premarket after U.S. President Donald Trump signed an executive order on Saturday, telling health regulators to speed up review of psychedelic drugs such as ibogaine and set aside $50 million for research

** Shares of Atai ATAI.O jump 21%, Definium Therapeutics DFTX.O rise 18%, Compass Pathways CMPS.O climb 24%, GH Research GHRS.O gain 19%, Enveric ENVB.O add 7% before the bell

** U.S.-listed shares of Cybin HELP.O up 15%

** Brokerage Jefferies says the order is an "official stamp of validation to the class", showing government support is "real/actionable (not rhetorical)"

** Ibogaine is a naturally occurring psychoactive compound derived from an African shrub that is being studied as a potential treatment for addiction and mental health disorders

** Psychedelic drugs with Breakthrough Therapy Designation may get Commissioner National Priority Review Vouchers, cutting FDA review from 6-10 month review time down to 1-2 months, Jefferies noted

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))